Psychedelic highlights | April 26 – 30

Shares :

5
(1)
Psychedelic highlights | April 26 – 30

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

COMPANYTICKERAPR 30WEEK %
Cybin Inc. CYBN$2.22+ 39.6 %
M2Bio SciencesWUHN$0.789+ 8.1 %
MindMedMMED$4.74+ 7.24 %
Revive TherapeuticsRVV$0.48+ 6.6 %
Field TripFTRP$5.79+ 5.2 %
CompassCMPS$36.29+ 3.1 %
Mind CureMCUR$0.42+ 0 %
NuminusNUMI$1.05– 2.7 %
Red Light HollandsTRIP$0.34– 2.8 %
Psyched WellnessPSYC$0.285– 16.10 %

Story of the week

1. Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury [news release]

Revive Therapeutics announce it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for Psilocybin to treat moderate to severe traumatic brain injury (“TBI”).

Read the full news HERE


2. Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab and Announces Q2 2021 Results [news release]

Numinus announced today that it has formed a partnership with KGK Science, a leading contract research organization with expertise in natural products, to undertake a new Psilocybin extraction clinical trial.

And more, Numinous announced its second quarter financial results for the three months ended February 28, 2021.

Read the full news HERE


3. Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 [news release]

Cybin announced that it has selected Alcohol Use Disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003.

Read the full news HERE


4. Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1 [news release]

Psyched Wellness announce that the company and its Clinical Research Organization partner, KGK Science, has commenced the next preclinical trial study with AME-1. 

Read the full news HERE


5. PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™ [news release]

PharmaTher Inc. announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity, based on the evaluation of the Company’s drug repurposing artificial intelligence (“AI”) platform, panaceAI™. 

Read the full news HERE


6. MINDCURE Announces Partnership with SOMA Breath Inc. and Shares Update on Strong Financial Position [news release]

Mind Cure  announce that it has entered into a partnership and licensing agreement with SOMA Breath Inc. (“SOMA Breath”).

And more, Mind Cure updates today on its financial position, near-term revenue strategy, timeline for iSTRYM’s market launch, as well as its research plans and products for both psychedelics and nootropics designed to accompany the use of psychedelic medicines.

Read the full news HERE


7. Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated and [news release]

Lobe Sciences  announce that it has entered into an agreement dated April 26th, 2021 with Virtual Psychedelics Incorporated (“VPI“)

And more, Lobe Sciences Enters into LOI with Core One Labs

Read the full news HERE


8. Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech and Appoints Patent Expert, Dr. Dan Polonenko, To Advisory Board [news release]

Core One Labs  announce that it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated April 23, 2021, pursuant to which it will acquire all of the outstanding share capital of Akome Biotech Ltd. (“Akome”).

and more, Core One Labs announce it has appointed Dr. Dan Polonenko to its Advisory Board, effective immediately. 

Read the full news HERE


8. Tryp Therapeutics Announces Q2 2021 Financial Results [news release]

Tryp Therapeutics announced its interim financial results for the three and six month periods ended February 28, 2021. 

Read the full news HERE


9. Red Light Holland and Halo Collective Create Red Light Oregon, Inc. – Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market [news release]

Red Light Holland’s announce that Articles of Incorporation have been filed with the Oregon Secretary of State to form Red Light Oregon, Inc., a 50/50 JV between Halo and Red Light Holland. 

Read the full news HERE


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.


Shares :